Véronique Freire, MD

CONTACT

Fidaa Al-Shakfa, M.sc.

CONTACT

Lead Sponsor

Centre hospitalier de l'Université de Montréal (CHUM)

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•Histological evidence of cancer.
•Spinal and vertebral bone metastases (T5 to L5) documented by imaging.
•Pain related to metastases ≥ 4 on a numerical scale 0-10.
•Karnofsky performance index \> 60 (ecog 0-2)
•Candidate for SBRT
•Less than 3 consecutive levels reached.
•Ability to complete follow-up questionnaires regarding pain, analgesics, and quality of life assessment.
•Potentially unstable lesions according to the spinal instability neoplastic score (SINS) scale (\> or = 7)

•Pregnancy or breastfeeding.
•Contraindications to MRI.
•Histology: myeloma, lymphoma or plasmacytoma.
•Radiotherapy prior to the level to be treated.
•Previous surgery at the site to be treated.
•Surgical indication:
•spinal instability neoplastic score (SINS) \> 13 or according to tumor board consensus.
•Bilsky score \> or = 2 Severe or progressive neurological signs (motor, incontinence).
•Lesion too large for safe vertebroplasty.
•High thoracic location not allowing safe visibility in fluoroscopy to perform vertebroplasty (T4 and above).
•Non-reversible coagulation disorders.
•Uncontrolled local or systemic infection.
•Estimated survival of less than 6 months.
•Inability or refusal to undergo SBRT treatment or vertebroplasty